Biometric practicesimple benchmark for complex dose finding studies

DOI10.1111/BIOM.12158MaRDI QIDQ5170208zbMATH OpenOpenAlexWikidataFDO

Authors Ying Kuen Cheung

Publication date 22 July 2014

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1111/biom.12158

zbMATH Keywords

phase I trialsefficacycombination therapyutility scoresmultiple toxicitiesphase I/II trialstoxicity tradeoff

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Recommendations

• Design efficiency in dose finding studies
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Dose Finding – A Challenge in Statistics
• Handbook of methods for designing, monitoring, and analyzing dose-finding trials
• Adaptive designs for dose-finding based on efficacy-toxicity response

Cites work

• A Random Walk Rule for Phase I Clinical Trials
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Adaptive designs for dose-finding based on efficacy-toxicity response
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• Coherence principles in dose-finding studies
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
• Dose-finding designs for HIV studies
• Non-parametric optimal design in dose finding studies
• Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose
• Statistical Methods for Rates and Proportions
• Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
• Stochastic approximation and modern model-based designs for dose-finding clinical trials
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials

Cited in

(11)

• A new design of the continual reassessment method
• Patient-specific dose finding in seamless phase I/II clinical trials
• scientific article; zbMATH DE number 1267952 (Why is no real title available?)
• A continual reassessment method without undue risk of toxicity
• Combined criteria for dose optimisation in early phase clinical trials
• Seamless phase I/II design for novel anticancer agents with competing disease progression
• A biomarker-based dose-schedule optimization design for immunotherapy trials
• Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression
• Using a dose-finding benchmark to quantify the loss incurred by dichotomization in phase II dose-ranging studies
• Potential outcome simulation for efficient head-to-head comparison of adaptive dose-finding designs
• scientific article; zbMATH DE number 4218086 (Why is no real title available?)

This page was built for publication: Biometric practicesimple benchmark for complex dose finding studies

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5170208)